Linong Ji

Jun 24, 2024 | nature.com | Peter Rossing |David M. Charytan |José Luis Gorriz |Linong Ji |Roland E. Schmieder

AbstractPeople with type-2-diabetes (T2D) and chronic kidney disease (CKD), have a high risk for kidney failure and cardiovascular (CV) complications. Glucagon-like-peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) independently reduce cardiovascular and kidney events. The effect of combining both is unclear.

Jan 22, 2024 | nature.com | Linong Ji

Dwibedi et al. carry out a randomized controlled trial to evaluate whether subgroups of patients with diabetes could receive the greatest metabolic benefit from novel anti-diabetic drugs. An increasing number of studies have been conducted to advance the clinical use of data-driven diabetes subclustering. Clinicians and researchers alike aim to understand whether and how these clusters can be leveraged to improve clinical decisions and patient treatment.

Dec 13, 2023 | nature.com | Linong Ji |Liming Chen |Shen Qu

AbstractMazdutide is a once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. We evaluated the efficacy and safety of 24-week treatment of mazdutide up to 6 mg in Chinese overweight adults or adults with obesity, as an interim analysis of a randomised, two-part (low doses up to 6 mg and high dose of 9 mg), double-blind, placebo-controlled phase 2 trial (ClinicalTrials.gov, NCT04904913).

Aug 8, 2023 | jamanetwork.com | Sam Dagogo-Jack |Justin B. Echouffo-Tcheugui |Leigh Perreault |Linong Ji

In Reply In his Letter about our recent Review article,1 Dr Entezari-Maleki suggests that SGLT2 inhibitors be considered in the treatment of prediabetes while noting that no drug treatment has yet been approved by the FDA for people with prediabetes. Clearly, the glucosuric effect of SGLT2 inhibitors decreases blood glucose levels in people with hyperglycemia. Additionally, the weight loss induced by SGLT2 inhibitors would be beneficial in people with prediabetes who have overweight or obesity.

May 25, 2023 | nature.com | Linong Ji

Inclusion and ethicsEthics review boards at each study site approved the protocol (see Supplementary Table 9 for the full list). The trial was conducted in accordance with the principles of international ethics guidelines, including the Declaration of Helsinki, and applicable laws and regulations. Written informed consent was obtained from each patient before any study procedures.